Concepts (110)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 14 | 2018 | 434 | 2.250 |
Why?
|
| Vitamin D Deficiency | 5 | 2018 | 10 | 1.410 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2013 | 59 | 0.750 |
Why?
|
| HIV Seropositivity | 3 | 2018 | 50 | 0.620 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 5 | 0.490 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2015 | 8 | 0.490 |
Why?
|
| Cytomegalovirus | 1 | 2015 | 15 | 0.490 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 37 | 0.490 |
Why?
|
| Antigens, CD | 1 | 2015 | 50 | 0.490 |
Why?
|
| Antibodies, Viral | 1 | 2015 | 50 | 0.480 |
Why?
|
| Anti-HIV Agents | 3 | 2011 | 61 | 0.480 |
Why?
|
| Cytomegalovirus Infections | 1 | 2015 | 33 | 0.480 |
Why?
|
| Vitamin D | 1 | 2013 | 31 | 0.400 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 13 | 0.400 |
Why?
|
| Insulin Resistance | 1 | 2013 | 50 | 0.400 |
Why?
|
| Health Status Disparities | 1 | 2013 | 73 | 0.380 |
Why?
|
| Middle Aged | 13 | 2018 | 8772 | 0.310 |
Why?
|
| Calcinosis | 1 | 2008 | 43 | 0.290 |
Why?
|
| Female | 16 | 2018 | 14734 | 0.280 |
Why?
|
| Coronary Artery Disease | 1 | 2008 | 124 | 0.260 |
Why?
|
| Cross-Sectional Studies | 5 | 2018 | 851 | 0.240 |
Why?
|
| RNA, Viral | 4 | 2013 | 44 | 0.230 |
Why?
|
| United States | 5 | 2017 | 1989 | 0.230 |
Why?
|
| Risk Factors | 4 | 2013 | 2237 | 0.230 |
Why?
|
| Humans | 17 | 2018 | 25967 | 0.220 |
Why?
|
| Viral Load | 2 | 2013 | 70 | 0.200 |
Why?
|
| Male | 12 | 2018 | 14277 | 0.190 |
Why?
|
| Adult | 9 | 2018 | 7662 | 0.180 |
Why?
|
| Prospective Studies | 3 | 2018 | 1701 | 0.170 |
Why?
|
| HIV-1 | 2 | 2013 | 205 | 0.150 |
Why?
|
| Immunosenescence | 1 | 2018 | 4 | 0.150 |
Why?
|
| Fish Oils | 1 | 2018 | 5 | 0.150 |
Why?
|
| Periodontal Attachment Loss | 1 | 2018 | 3 | 0.140 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2013 | 49 | 0.140 |
Why?
|
| Cytokines | 1 | 2018 | 225 | 0.130 |
Why?
|
| Inflammation | 1 | 2018 | 267 | 0.130 |
Why?
|
| Loneliness | 1 | 2017 | 54 | 0.130 |
Why?
|
| Cognitive Aging | 1 | 2017 | 77 | 0.120 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 71 | 0.120 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 294 | 0.110 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2013 | 11 | 0.100 |
Why?
|
| Cyclohexanes | 1 | 2013 | 2 | 0.100 |
Why?
|
| Aged | 4 | 2017 | 8732 | 0.100 |
Why?
|
| Triazoles | 1 | 2013 | 29 | 0.100 |
Why?
|
| Insulin | 1 | 2013 | 84 | 0.100 |
Why?
|
| Blood Glucose | 1 | 2013 | 102 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2013 | 251 | 0.100 |
Why?
|
| Graft vs Host Disease | 1 | 2013 | 54 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2013 | 99 | 0.100 |
Why?
|
| Vaginosis, Bacterial | 1 | 2011 | 16 | 0.090 |
Why?
|
| Women's Health | 1 | 2013 | 173 | 0.090 |
Why?
|
| HIV | 1 | 2011 | 39 | 0.090 |
Why?
|
| Fatty Alcohols | 1 | 2011 | 6 | 0.090 |
Why?
|
| Anticholesteremic Agents | 1 | 2011 | 14 | 0.090 |
Why?
|
| Medically Underserved Area | 1 | 2011 | 16 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 160 | 0.090 |
Why?
|
| Dyslipidemias | 1 | 2011 | 16 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2013 | 449 | 0.090 |
Why?
|
| Disease Progression | 1 | 2013 | 655 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2011 | 268 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2017 | 1806 | 0.080 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 4641 | 0.080 |
Why?
|
| Brain | 2 | 2008 | 1569 | 0.080 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 990 | 0.070 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2007 | 8 | 0.070 |
Why?
|
| Drug Resistance, Viral | 1 | 2007 | 13 | 0.070 |
Why?
|
| Young Adult | 1 | 2013 | 1941 | 0.070 |
Why?
|
| Depressive Disorder | 1 | 2008 | 172 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 307 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 648 | 0.060 |
Why?
|
| Chicago | 2 | 2018 | 898 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2018 | 393 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 1757 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2011 | 152 | 0.040 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2018 | 21 | 0.040 |
Why?
|
| Midwestern United States | 1 | 2018 | 48 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2018 | 58 | 0.040 |
Why?
|
| Prevalence | 1 | 2018 | 433 | 0.030 |
Why?
|
| Biomarkers | 1 | 2018 | 544 | 0.030 |
Why?
|
| CCR5 Receptor Antagonists | 1 | 2013 | 1 | 0.030 |
Why?
|
| HIV Fusion Inhibitors | 1 | 2013 | 2 | 0.030 |
Why?
|
| Lymphoid Tissue | 1 | 2013 | 10 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2013 | 29 | 0.030 |
Why?
|
| Rectum | 1 | 2013 | 50 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2013 | 41 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2013 | 82 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 1107 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2011 | 26 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2011 | 29 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2011 | 64 | 0.020 |
Why?
|
| Triglycerides | 1 | 2011 | 56 | 0.020 |
Why?
|
| Urban Population | 1 | 2011 | 149 | 0.020 |
Why?
|
| Health Behavior | 1 | 2011 | 157 | 0.020 |
Why?
|
| Cognition | 1 | 2017 | 1250 | 0.020 |
Why?
|
| Anisotropy | 1 | 2008 | 42 | 0.020 |
Why?
|
| Aging | 1 | 2017 | 1483 | 0.020 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2007 | 3 | 0.020 |
Why?
|
| HIV Protease | 1 | 2007 | 4 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 868 | 0.020 |
Why?
|
| Affect | 1 | 2008 | 59 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2007 | 83 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 165 | 0.020 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2007 | 93 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2008 | 296 | 0.020 |
Why?
|
| Genotype | 1 | 2007 | 339 | 0.020 |
Why?
|
| Radiography | 1 | 2007 | 616 | 0.020 |
Why?
|
| Mutation | 1 | 2007 | 341 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2008 | 1150 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 1059 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2007 | 3399 | 0.010 |
Why?
|